Cowen and Company reaffirmed their market perform rating on shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in a research report report published on Wednesday. The firm currently has a $18.00 target price on the stock, down from their previous target price of $30.00.

TEVA has been the topic of a number of other research reports. Royal Bank Of Canada dropped their price target on shares of Teva Pharmaceutical Industries Limited from $21.00 to $15.00 and set an underperform rating on the stock in a research note on Monday, September 18th. Credit Suisse Group set a $39.00 price target on shares of Teva Pharmaceutical Industries Limited and gave the company a buy rating in a research note on Thursday, August 3rd. Maxim Group reissued a hold rating and issued a $15.50 price target on shares of Teva Pharmaceutical Industries Limited in a research note on Thursday, September 14th. Cantor Fitzgerald set a $31.00 price target on shares of Teva Pharmaceutical Industries Limited and gave the company a hold rating in a research note on Thursday, June 22nd. Finally, Vetr raised shares of Teva Pharmaceutical Industries Limited from a hold rating to a buy rating and set a $34.17 price target on the stock in a research note on Monday, July 24th. Five investment analysts have rated the stock with a sell rating, eighteen have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of Hold and a consensus target price of $27.63.

Teva Pharmaceutical Industries Limited (TEVA) opened at 15.94 on Wednesday. Teva Pharmaceutical Industries Limited has a 12 month low of $15.22 and a 12 month high of $45.85. The company’s market cap is $16.20 billion. The company’s 50 day moving average is $16.91 and its 200-day moving average is $26.76.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The company had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.72 billion. During the same period in the prior year, the business posted $1.25 EPS. Teva Pharmaceutical Industries Limited’s revenue was up 12.9% compared to the same quarter last year. On average, analysts expect that Teva Pharmaceutical Industries Limited will post $4.28 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was first published by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/teva-pharmaceutical-industries-limiteds-teva-market-perform-rating-reaffirmed-at-cowen-and-company/1617144.html.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 14th. Investors of record on Tuesday, August 29th were issued a $0.085 dividend. The ex-dividend date was Friday, August 25th. This represents a $0.34 annualized dividend and a yield of 2.13%. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is currently -15.36%.

Institutional investors and hedge funds have recently modified their holdings of the stock. San Francisco Sentry Investment Group CA purchased a new stake in Teva Pharmaceutical Industries Limited in the 2nd quarter valued at about $106,000. Kistler Tiffany Companies LLC raised its holdings in Teva Pharmaceutical Industries Limited by 74.7% in the 2nd quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock valued at $122,000 after buying an additional 1,571 shares during the period. Bronfman E.L. Rothschild L.P. raised its holdings in Teva Pharmaceutical Industries Limited by 2.6% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock valued at $123,000 after buying an additional 94 shares during the period. FNY Managed Accounts LLC purchased a new stake in Teva Pharmaceutical Industries Limited in the 1st quarter valued at about $123,000. Finally, Sterling Investment Advisors Ltd. raised its holdings in Teva Pharmaceutical Industries Limited by 2.6% in the 1st quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after buying an additional 100 shares during the period. Hedge funds and other institutional investors own 56.77% of the company’s stock.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.